You just read:

CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

News provided by

CTI BioPharma Corp.

Aug 29, 2016, 06:00 ET